Development of Ligand-Drug Conjugates Targeting Melanoma through the Overexpressed Melanocortin 1 Receptor

Area of Science:

• Oncology
• Medicinal Chemistry
• Dermatology

Background:

• Melanoma is a dangerous skin cancer with increasing resistance to current therapies like BRAF-V600E and PD-1 inhibitors.
• Drug resistance remains a significant challenge in melanoma treatment, necessitating novel therapeutic strategies.

Purpose of the Study:

• To design and synthesize novel ligand-drug conjugates for targeted melanoma therapy.
• To overcome drug resistance in melanoma by selectively delivering cytotoxic agents.

Main Methods:

• Conjugation of cytotoxic drugs with melanotan-II (MT-II), a melanocortin 1 receptor (MC1R) agonist.
• In vitro evaluation of conjugate binding to MC1R and selective drug delivery to A375 melanoma cells.
• Assessment of camptothecin-MT-II conjugate efficacy in inhibiting melanoma cell growth.

Main Results:

• Drug-MT-II conjugates demonstrated strong binding to MC1R and selective delivery to A375 melanoma cells.
• Camptothecin-MT-II (compound 1) effectively inhibited A375 melanoma cell proliferation with an IC50 of 16 nM.
• The MC1R-targeting approach enhances options for cytotoxic drug selection against resistant melanoma.

Conclusions:

• Ligand-drug conjugates targeting MC1R offer a promising strategy to overcome melanoma drug resistance.
• Selective drug delivery via MT-II moiety provides a versatile platform for developing new melanoma therapies.
• This approach holds potential for addressing the critical challenge of cancer resistance in melanoma.